Patients without nephrotoxicity (n = 76) | Patients with nephrotoxicity (n = 26) | P | Patients without nephrotoxicity (n = 52) | Patients with nephrotoxicity (n = 50) | P | |
---|---|---|---|---|---|---|
Day 7 | EOT | |||||
Age, years* | 66.5 (24–91) | 73 (41–84) | 0.036 | 65 (24–91) | 72.5 (30–87) | 0.016 |
Male sex | 61 (80.3) | 18 (69.2) | 0.281 | 40 (76.9) | 39 (49.4) | 1 |
Charlson Index* | 4.12 ± 2.58 | 5.5 ± 2.34 | 0.031 | 3.6 ± 2.4 | 5.36 ± 2.3 | 0.001 |
APACHE II | 14.9 ± 6.4 | 14.8 ± 7 | 0,32 | 15.3 ± 6 | 14.2 ± 7 | 0,16 |
Clinical status: | ||||||
- Severe sepsis | 39 (51.3) | 9 (34.6) | 0.175 | 24 (46.2) | 24 (48) | 1 |
- Shock | 7 (9.2) | 1 (3.8) | 0.457 | 7 (13.5) | 1 (2) | 0.06 |
Acute renal failure at baseline | 11 (14.5) | 4 (15.4) | 1 | 4 (7.7) | 11 (22) | 0.052 |
1CKD at baseline | 17 (22.3) | 6 (23) | 1 | 11 (21.15) | 12 (24) | 0.81 |
Albumin* | 2.8 ± 0.62 | 2.5 ± 0.62 | 0.047 | 2.8 ± 0.62 | 2.6 ± 0.62 | 0.031 |
1BMI (Kg/m2)* | 25.6 ± 5.9 | 24.3 ± 5.03 | 0.26 | 25.2 ± 5 | 25.4 ± 6.35 | 0.75 |
3CMS total dose (MU)* | 35.1 ± 15.15 | 42 ± 15.84 | 0.06 | 97.3 ± 106.35 | 103.9 ± 78.5 | 0.047 |
Duration of CMS treatment, days* | 18.7 ± 16.6 | 21.02 ± 14.42 | 0.047 | |||
4Cmin, mg/mL* | 0.78 (0.11-3.2) | 3.11 (0.45-5.99) | <0.0001 | 0.7 (0.11-5.7) | 1.18 (0.16-5.99) | <0.0001 |
5Cmax, mg/mL* | 0.78 (0.15-3) | 3.2 (0.68-6.62) | <0.0001 | 0.74 (0.15-6.10) | 1.81 (0.16-6.62) | <0.0001 |
Concomitant aminoglycoside use | 24 (31.6) | 8 (30.8) | 1 | 16 (30.8) | 16 (32) | 1 |
Concomitant vancomycin use | 8 (10.5) | 1 (3.8) | 0.442 | 3 (5.8) | 6 (12) | 0.314 |
Concomitant 6NSAID use | 11 (14.5) | 4 (15.4) | 1 | 3 (5.8) | 12 (24) | 0.012 |
Concomitant loop diuretic use | 31 (40.8) | 15 (57.7) | 0.172 | 16 (30.8) | 30 (60) | 0.005 |
Other concomitant nephrotoxic drugs | 17 (22.4) | 4 (14.4) | 0.579 | 13 (25) | 8 (16) | 0.33 |
≥ 2 nephrotoxic drugs | 37 (48.7) | 13 (50) | 1 | 20 (38.5) | 30 (60) | 0.047 |